GlassScriptPhysician profile
Erick Argueta
NPI 1083144638
$4,607.04
in general payments reported to CMS, 2019-2025
17 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2021: $316 · 2022: $210 · 2023: $132 · 2024: $2,329 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,590 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,590.36 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,369.49 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $827.18 | 2019-2025 | |
| Pfizer INC. | $500.79 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $372.51 | 2024-2025 | Voquezna |
| Steris Corporation | $309.84 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $248.29 | 2024 | |
| Intercept Pharmaceuticals, INC. | $240.55 | 2019 | |
| Boston Scientific Corporation | $220.03 | 2021-2022 | |
| Exact Sciences Corporation | $124.51 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.69 | 2024-2025 | Xifaxan |
| Celltrion USA INC. | $86.29 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $52.55 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $49.56 | 2024 | Entyvio |
| Madrigal Pharmaceuticals | $40.30 | 2025 | Rezdiffra |
| Genzyme Corporation | $29.50 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $23.79 | 2019 | |
| Braintree Laboratories, INC. | $22.17 | 2025 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Argueta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.